Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Boehringer discontinues brigimadlin while others continue to struggle.
The group could soon provide clarity on CTX112’s regulatory path.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
The THIO-104 study listing is live, along with questions about funding the trial.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.
